Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: Evidence for chronic exposure to LPS. Expression of CDI4 on peripheral blood monocytes and serum levels of the 53 kD soluble CD14 antigen were investigated in patients with end-stage renal failure who were undergoing chronic hemodialysis (HD) with either cuprophane/ hemophane (CU/HE) low-flux (LF) or polysulfone/polyamide (PS/PA) high-flux (HF) membranes. Baseline expression of CD14 was significantly lower in HD patients compared to uremic patients and normal controls. Patients using PS/PA membranes disclosed a further decreased CD14 expression than patients with CU/HE membranes. Specific fluorescence intensity for CD14 increased 15 minutes after the start of the dialysis session and was on average 22% higher after hemodialysis. The serum levels of sCD14 were elevated about 2.5-fold in HD patients compared to healthy controls (5.4 1.3 vs. 2.2 0.5 mg/liter, P < 0.0001) and were significantly higher compared to non-dialyzed patients with chronic renal failure (3.9 1.0 mg/liter, P <0.001). After regular dialysis with high-flux membranes, soluble CD14 serum concentrations significantly increased (P < 0.001) compared to pre-dialysis levels. Values of soluble CD8 (54 kD) were elevated only 1.5-fold in HD patients relative to healthy controls, whereas serum levels of the low molecular weight soluble CD23 (20 kD) 12 and 19-fold in patients treated with HF-HD and LF-HD, reflecting the renal impairment and filtration through HF membranes.
related to hemodialysis is not well understood. An altered macrophage Fe-receptor function in vivo [8] and a reduced phagocytic capacity in vitro [9] have been reported. However, most studies focused on the release of monocyte-derived cytokines (IL-I, IL-6, TNF-a) under in vitro conditions [10] [11] [12] [13] [14] , or on the determination of cytokine serum levels [15-18; reviewed 19] . Overall, these data suggest that hemodialysis is associated with monocyte activation.
At present, it is still unclear if such monocyte activation occurs primarly through contact with the membrane material or is due to endotoxin transfer across the dialyzer membrane during hemodialysis. The transmembrane passage of LPS or LPS-fragments from the dialysate to the blood compartment is, although not undoubted, documented by numerous reports [20] [21] [22] . The activation of monocytes through LPS occurs via specific cell-surface antigens that act as receptors for the lipid-A moiety of LPS [23] . One known receptor for LPS is the 55 kD glycosyl-phosphatidylinositol (GPI)-anchored myeloid differentiation antigen CDI4 which is expressed on peripheral blood monocytes and macrophages [24, 25] . Upon entry into the bloodstream LPS is cornplexed to LPS-binding protein (LBP) [261, a 60 kD serum protein with a lipid-A binding site [271. This LBP/LPS complex then recognizes the cell surface CDI 4 antigen on monocytes/macrophages [25, 28, 291 , leading to an enhanced cytokine production [30, 311. However, the exact molecular basis of the CD14-mediated events is unknown. In this regard, a 53 kD soluble form of CD14 (sCD14) detectable in human serum [32] and monocyte culture supernatants [33] may have immunological relevance. Recently, it has been reported that the LPS-induced activation of cells that do not themselves express CD14 is mediated by soluble CD14 [34, 35] . Thereby high concentrations of LPS induce an activation in the presence of sCD14 alone, whereas at low LPS concentrations the sCD14-stimulated activation was strongly enhanced by LPSbinding protein [36] . This indicates that the membrane form of CD14 behaves as a LPS receptor, and its soluble form may serve as a co-ligand for LPS-mediated cell activation.
In the present study we investigated changes in the expression of CD14 on peripheral blood monocytes from patients undergoing hernodialysis who also show augmented sCD14 serum levels. Furthermore, we assessed the influence of LPS, which apparently plays a critical role in extracorporal blood purification, on CD14 expression and sCDI4 release under in vitro conditions.
Methods

Patient characteristics
Twenty-five patients on chronic maintenance hemodialysis (HD) were selected for study after informed consent was obtained. The mean age was 51.6 (range 27 to 73) with a mean time of hemodialysis treatment of seven years (range 2 to 14) prior to the study. All patients had stable disease and underwent four to five hours of maintenance hemodialysis thrice weekly. Except for medication including phosphate binders, multivitamins, ACEinhibitors and calcium antagonists, none received drugs known to interfere with the immunoresponse at the time of the study.
Patients on HD received a normocaloric diet and were placed on a low water and potassium intake. Patients were dialyzed with standard capillary artifical kidneys. Low flux dialyzers made from cuprophane (alpha-600; Gambro, Hechingen, Germany; N = 7) or hemophane (GFS-16; Gambro; N = 6) as well as polysulfone (HF-60, Fresenius, Bad Homburg, Germany; N = 8) or polyamide (GFS-16; Gambro; N = 4) high flux dialyzers were used. Blood flow was between 150 to 220 mi/mm. Water produced by reverse osmosis and concentrate were distributed by distinct loops. The dialysate routinely used contained bicarbonate (34 mmol/liter) and acetate (3 mmol/liter).
For determination of soluble leukocyte antigens in addition frozen serum specimens of 12 patients undergoing long-term hemodialysis were analyzed. These specimens were stored at -22°C for one to six months until used. Twenty-one non-dialyzed patients with chronic renal failure (creatinine 3 to 10 mg/dl) were also tested. The underlying diseases (chronic glomerulonephritis, interstitial nephropathy, polycystic kidney disease, diabetic nephropathy or unknown etiology) of all patients contributing to the present study were documented. Twenty-seven healthy subjects from our clinical staff were recruited as normal controls.
Collection of blood samples
Blood samples were collected from the arterial site of the arteriovenous fistula at the beginning of HD and from the arterial blood line after HD. For the determination of soluble leukocyte antigens blood was drawn into Serum-Monovetten (Sarstedt, Nümbrecht, Germany). Tubes were allowed to stand for 30 minutes for clotting and were then centrifuged at 1800 g. Sera were aliquoted and stored at -22°C for further use. For immunophenotyping of peripheral blood monocytes blood was drawn into tubes containing EDTA as an anticoagulants (EDTA-Monovetten, Sarstedt, Germany) and directed to flow cytometric analysis within 30 minutes after venipuncture as described below. tensity of the gated monocytes was measured using four-decade logarithmic amplification for CD14 and the isotype control staining. For the determination of specific CD14 expression the difference in fluorescence intensity between CD14 and control stains was calculated ( Fig. 1) . The results were expressed as mean fluorescence channel (MFC).
Measurement of soluble leukocyte antigens sCD14, sCD8 and sCD23
For determination of soluble CD14 in serum specimens and cell culture supernatants, a sandwich ELISA applying two monoclonal antibodies (IBL, Hamburg, Germany) was used as described previously [32] . Serum levels of soluble sCD8 and soluble sCD23 were assessed using two sandwich ELISAs (CellFree CD8, T Cell Science, Cambridge, MA, USA, and sCD23 EIA Kit, The Binding Site, Heidelberg, Germany). The assays were performed according to the manufacturer's specifications.
Measurement of other serum proteins and determination of hemoconcentration
To determine the effect of dialysis using high-flux membranes on serum concentrations of soluble CD14, 32-microglobulin (11.8 The shifts on hemoconcentration during hemodialysis were evaluated by measuring the hematocrit in EDTA-blood with an automated cell counter (Coulter counter, Coulter Electronics Inc., Hialeah, FL, USA) before and after the dialysis session. Values of serum protein determinations after HD were then corrected for changes in hemoconcentration.
Determination of the influence of LPS on CDI4 expression in whole blood samples
LPS (E. coli serotype 055:B5, Sigma, München, Germany) was resuspended and further diluted in PBS. Whole blood from nine healthy donors (white blood cell count: 5700 to 8000, mean 6540, leukocytes/jxl; 307 to 442, mean 364, monocytes/xl) was collected in EDTA-tubes and directly used for the experiment. One milliliter of whole blood was supplemented with 20 pd PBS or 20 jxl of a LPS solution to give a final LPS concentration of 0.01 ng/ml or 1 ng/ml. Tubes were mounted on a laboratory shaker and incubated at room temperature under gentle rotation. Directly and after 15, 30, 60, 120 and 240 minutes 100 xl aliquots were collected and directed to flow cytometric analysis as described above.
Preparation of peripheral blood monocytes
Whole blood from normal healthy donors collected in EDTAtubes was mixed in a ratio 10:1 with a solution of 6% Dextran T500 (Pharmacia, Freiburg, Germany) suspended in PBS and incubated for 40 minutes at room temperature. Then the leukocyte-rich plasma was removed and carefully layered on top of a high osmolarity gradient medium (NycoPrep 1.068; Nycomed, Norway). After centrifugation for 15 minutes at 600 g the monocyte ring was collected and the pooled monocyte fractions were then washed twice with ice-cold PBS. The purity of CD14 cells was evaluated by flow cytometry analysis using the FITClabeled anti-CD14 antibody as described above. Absolute numbers of cells were counted in a Neubauer microchamber. On average 57% (49 to 66%) of the isolated cells were CD14 monocytes.
Release of soluble CD14 by cultured monocytes
Isolated peripheral blood monocytes were cultured at a density of 2 X i0 cells/mi in RPM! 1640 medium supplemented with 10% fetal calf serum (Gibco, Life Technologies, Germany) and 200 mrvi glutamine without any antibiotics. Cultures were performed in 48-well plates (Falcon, Heidelberg, Germany) with 0.5 ml cell suspension per well. For testing the stimulating effect of LPS on sCD14 release, cells were cultured in the presence of 1 ng/ml or 0.01 ng/ml LPS (E. coli 055:B5). Culture supernatants were collected and stored at -22°C until measurement of sCD14.
Statistical analysis
Statistical analyses were performed with the software "BIAS" Biomathematics, University of Frankfurt/Main, Germany. Differences in parameters between two groups were elvaluated with the Mann-Whitney U-Test. Two-tailed Student's i-test was used to compare differences in parameters before and after hemodialysis. P values less than 0.05 were considered significant.
Results
Monocyte membrane CD14 expression in non-dialyzed and dialyzed subjects
Baseline CD14 expression of peripheral blood monocytes from normal controls or stable hemodialysis patients without infections was relatively constant. In a longitudinal study the CDI4 expression for two HD patients and two normal controls was tested weekly for five weeks, and the variations (mean deviation from the mean value) were 4.5%, 2%, 3.5%, and 6.9%, respectively. However, monocytic CD14 expression markedly increased in early stages of infections, even before onset of clinical symptoms (Nockher, unpublished results). Those patients and controls with beginning infectious diseases were excluded retrospectivly from the study.
CD14 expression was significantly lower in patients undergoing long-term hemodialysis compared to uremic patients and normal controls (mean CD14 fluorescence intensity MFC: 500 53 vs. 657 138, P < 0.0001 and 654 113, P < 0.0001). Furthermore, CD14 expression is also influenced by the type of dialysis membrane used (Fig. 2) . Baseline CD14 expression was more decreased in patients using polysulfone or polyamide high-flux membranes than in patients with cuprophane or hemophane low-flux dialyzers (MFC 469 45 vs. 529 42, P = 0.003). In uremic patients without HD treatment cell surface CDI4 did not differ from healthy controls.
Effect of hemodialysis on CD14 expression
Determination of monocyte CD14 expression before and after a four-hour hemodialysis session revealed a noticeable increase in the cell surface CD14 (Fig. 3) . Mean CDI4 expression was on average 22% (range 1 to 53%) higher after hemodialysis, with no significant difference between the various membranes types used. However, in patients using polysulfone/polyamide membranes, pared for two patients in four consecutive dialysis sessions. In one patient the mCD14 increase varied between 14 and 32%. However, in the second patient a relativly constant rise of 19, 24, 28 and 24% was observed. We also analyzed the profile of intradialytic changes in CD14 expression during HD in two stable patients. In both cases cell surface CD14 was increased 15 minutes after start of the dialysis session and a further continous rise during HD was observed ( Fig. 4 ).
Serum concentrations of sCDJ4 compared with sCD8 and sCD23 in non-dialyzed and dialyzed subjects
In patients with chronic renal failure without hemodialysis treatment, serum concentrations of the soluble CD14 antigen were augmented relative to the values in healthy individuals. However, the mean sCD14 level in serum specimens from stable long-term hemodialyzed patients was significantly higher compared to non-dialyzed patients with chronic renal failure, and about 2.5-fold higher compared to normal controls (Table 1) . No difference in serum sCD14 was found between patients using high-flux or low-flux dialyzers. In HD patients with acute or chronic infections a further rise in sCD14 levels (up to 10 mg/liter), and a positive correlation with the acute phase protein CRP emerged. In addition, the soluble T cell antigen sCD8 was elevated in HD-patients regardless of the membrane type (P < 0.0001). However, serum values were only 1.5-fold higher compared to healthy subjects. In contrast, the serum concentrations of the low molecular weight sCD23 antigen were depended on the type of the dialysis membrane used. Patients treated with high-flux membranes disclosed about 12-fold elevated sCD23 serum concentrations compared to normal controls, and a further increase was observed by patients using low-flux membranes ( Table 1) .
Influence of hemodialysis on sCD14 levels
The influence of the dialysis procedure on sCD14 serum levels was studied in HD patients treated with polysulfone high-flux membranes. In parallel, levels of p2-microglobulin and hemopexin were measured, monitoring changes in serum protein concentrations during HD. The low molecular weight 32-microglobulin Pre-HD Post-HD CD14 increase was slightly higher compared to those on cuprophane/hemophane membranes (median increase 26.8% vs. 19 .9%). Intraindividual changes of CD14 expression were corn- Soluble leukocyte antigens were determined in serum from healthy controls, non-dialyzed patients with chronic renal failure (CRF) and hemodialysis patients treated with low-flux (HD-LF) or high-flux (HD-HF) membranes. Results are expressed as mean sii Statistical comparisons between the patients groups have been obtained using the Mann-Whitney U test. a versus controls versus CRF HD-HF versus HD-LF ND is not determined.
(11.8 kD), heavily accumulated in long-term hemodialyzed patients, is known to be eliminated by high-flux membranes. Hemopexin, a liver-derived 53 kD protein with the identical molecular weight of sCDI4, was used as additional marker since normally hepatic protein synthesis is not influenced by HD. The results are summarized in Table 2 .
As expected, f32-microglobulin levels markedly dropped during HD due to filtration through HF-membranes. Serum levels of hemopexin did not change, indicating no loss of this 53 kD protein during hemodialysis. However, determination of soluble CDI4 revealed a slight but statistically significant increase in sCD14 serum concentrations after the dialysis session. Taken together, these clinical studies clearly demonstrate the up-regulation of CD14 expression by peripheral blood monocytes during hemodialysis. Also, levels of the soluble CD14 antigen were more elevated in HD patients relative to CRF patients without HD treatment, indicating an enhanced release of the CD14 antigen during HD demonstrated by increased serum levels after hemodialysis.
Influence of LPS on CD14 expression in whole blood samples
To establish the influence of endotoxin on monocyte CDI4 expression in whole blood, we assessed in in vitro experiments the changes of cell surface CD14 in response to LPS over a four-hour incubation period.
The expression of CD14 on monocytes was found to slowly increase after blood collection, while addition of LPS led to a pronounced stimulation of CD14 expression (Table 3) . A strong increase in CDI4 expression was already found after 30 minutes of incubation by challenge with I nglml LPS. After 60 minutes, 0.01 nglml LPS also significantly increased cell surface CDI4 as compared to the controls.
The mean CD14 increase per minute ( MFC/min) was maximal in the first 30 minutes by addition of 1 nglml LPS (9.6 MCF/min) and between 30 and 60 minutes for 0.01 ng/ml LPS (6.2 MFC/min) followed by a continous decline. After 120 minutes the up-regulation of membrane-bound CDI4 was nearly completed. Serum protein levels were determined from 12 patients treated with high-flux polysulfone membranes for 4 hours. Values after hemodialysis were corrected for hemoconcentration. Two-tailed Student's t-test was used for statistical analysis. NS is not significant.
Effect of LPS on sCD14 release of cultured peripheral blood monocytes
The effect of lipopolysaccharide on the release of the sCDI4 antigen by human monocytes was determind by incubating purified monocytes in the presence or absence of LPS for five days, and measuring sCDI4 in culture supernatants. The results are shown in Figure 5 . Soluble CD14 concentrations in supernatants of untreated monocytes subsequently increased during culture. Addition of 0.01 or 1 nglml LPS significantly enhanced sCD14 concentrations after one day and maintained elevated release of the sCD14 antigen during the following four days.
Discussion
With their multiple immunobiological activities monocytes! macrophages play a central role in regulating the immune response. In the last decade a number of investigations reported disturbances in monocyte function on hemodialysis. However, whereas most studies have looked at various aspects of cytokine secretion, information about the expression of cell surface antigens with respect to monocyte activation is limited. In this report, we describe the up-regulation of the cell surface expression of the monocyte CD14 antigen after a dialysis session together with a reduced baseline CD14 expression and elevated serum levels of the soluble CDI4 antigen.
The changes of membrane antigen expression such as CD14, HLA-DR [13] and complement receptors [37] by peripheral blood moriocytes reflect a state of activation induced by the hemodialysis procedure. In vivo stimulation of monocytes during HD was also described by other investigators. Spontaneous production of TNF-a by cultured peripheral blood monocytes obtained from HD patients was enhanced as compared to monocytes from controls [38] . Furthermore, after HD an increased spontaneous IL-I [10] or TNF-a [11, 38] secretion compared to the predialysis state has been reported. These in vitro data are supported by in vivo results, where increased serum levels of IL-1f3 [39] or TNF-cw were observed 60 minutes after start of the dialysis session [11] . Several mechanisms of monocyte activation during hemodialysis have been proposed. The direct interaction with the artifical surface of the dialyzer membrane has been favored as the primary mechanism [40] . In addition, exposure to bacterial endotoxin through transmembrane passage of LPS is thought to be an important factor in the monocyte activation process [20, 22, 41] . Recent work from different laboratories showed that the CD14 antigen mediates monocyte recognition of lipopolysaccharide [25, 30, 31, 42] . In our in vitro studies LPS concentrations as low as 
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Whole blood specimens from nine healthy donors were incubated for 4 hours with 0.01, 1 ng/ml or without LPS at room temperature, and monocyte CD14 expression was evaluated directly and after 15, 30, 60, 120 At the moment the reason for the further decreased baseline CD14 expression in patients treated with high-flux polysulfone or polyamide devices remains unclear. Polyamide membranes were reported to have a lower transmembrane passage of LPS due to LPS absorption through hydrophobic interactions [45, 46] . On the other hand, the contact with the different chemical composition of the membrane surface material could also influence CD14 expression. However, further studies are necessary to investigate the direct influence of the membrane materials on cell surface CD14.
Consistent with earlier reports from our laboratory, the release of soluble CD14 was increased from cultured peripheral blood monocytes treated with lipopolysaccharide. Only trace amounts of LPS were necessary to increase sCD14 release (10 pg/ml) or IL-13 secretion (0.1 pg/mI, unpublished data). The enhanced sCD14 5 release is thought to be a result of the increased cell surface CD14, since shedding of the membrane antigen is reported to be a mechanism of down-modulation on stimulated monocytes [47] . Thus, the elevated sCD14 serum concentrations in HD patients apparently reflect not only the renal impairment but also a repeated stimulation of CD14 expression with subsequent release of sCD14 during each dialysis session, as could be demonstrated by the increased serum levels after HD. This explains why the increments in serum concentrations of the 53 kD sCD14 [48] and the 54 kD sCD8 [49] molecules, both normally filtered by the glomerulus at minimal rates, differ in HD patients compared to healthy subjects. The significantly elevated sCD14 in HD patients relative to non-dialyzed patients with CRF gives further impact for the influence of HD-treatment on sCD14 release. The 20 kD sCD23 antigen [50] is even more accumulated in HD patients compared to healthy controls, due to loss of renal filtration and shedding of the CD23 antigen during HD, the latter resulting in a marked rise in sCD23 serum levels after HD [51] .
The physiological importance of elevated sCD14 serum levels in hemodialysis is not yet clear. HD-patients with chronic HCV infection or acute bacterial infections have significant increased sCD14 values compared to stable HD patients [52] . In any case, sCD14 participates as an accessory molecule in LPS-induced changes in various cell functions [36, 53, 54] . Therefore, elevated sCD14 serum levels may enhance cellular effects mediated by LPS and/or LBP-CD14 complexes. In addition, the reduced basal CD14 expression in HD patients may account for a decreased stimulatory capacity of monocytes by endotoxins, resulting in an impaired immunoresponse to bacterial infections.
In conclusion, our results presented herein show that long-term hemodialysis leads to an ongoing stimulation of monocyte CD14 120 100 80 860 .g 40 0 20 0 * expression which may result in the decreased baseline CD14 expression and elevated sCD14 serum levels. However, whether changes in CD14 expression and sCD14 release contribute to a disturbed immune response to infections in HD patients will require further investigation. Also, the prevention of chronic exposure to even trace amounts of endotoxin during hemodialysis remains a challenge for the future. 
